209 related articles for article (PubMed ID: 34746691)
41. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
[TBL] [Abstract][Full Text] [Related]
42. Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes.
Sookoian S; Pirola CJ
Sci Rep; 2016 Jun; 6():27718. PubMed ID: 27278285
[TBL] [Abstract][Full Text] [Related]
43. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.
Pirola CJ; Sookoian S
Hepatology; 2015 Dec; 62(6):1742-56. PubMed ID: 26331730
[TBL] [Abstract][Full Text] [Related]
44. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.
O'Hare EA; Yang R; Yerges-Armstrong LM; Sreenivasan U; McFarland R; Leitch CC; Wilson MH; Narina S; Gorden A; Ryan KA; Shuldiner AR; Farber SA; Wood GC; Still CD; Gerhard GS; Robishaw JD; Sztalryd C; Zaghloul NA
Hepatology; 2017 May; 65(5):1526-1542. PubMed ID: 28027591
[TBL] [Abstract][Full Text] [Related]
45. The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.
Prill S; Caddeo A; Baselli G; Jamialahmadi O; Dongiovanni P; Rametta R; Kanebratt KP; Pujia A; Pingitore P; Mancina RM; Lindén D; Whatling C; Janefeldt A; Kozyra M; Ingelman-Sundberg M; Valenti L; Andersson TB; Romeo S
Sci Rep; 2019 Aug; 9(1):11585. PubMed ID: 31406127
[TBL] [Abstract][Full Text] [Related]
46. TM6SF2 Determines Both the Degree of Lipidation and the Number of VLDL Particles Secreted by the Liver.
Reyes-Soffer G; Liu J; Thomas T; Matveyenko A; Seid H; Ramakrishnan R; Holleran S; Zaghloul N; Sztalryd-Woodle C; Pollin T; Ginsberg HN
medRxiv; 2023 Jun; ():. PubMed ID: 37425717
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
[TBL] [Abstract][Full Text] [Related]
48. [Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han Population of China's Northeast region].
Bing H; Wang W; Li YL
Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):156-162. PubMed ID: 33685085
[No Abstract] [Full Text] [Related]
49. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
50.
Liu S; Murakami E; Nakahara T; Ohya K; Teraoka Y; Makokha GN; Uchida T; Morio K; Fujino H; Ono A; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes NC; Imamura M; Aikata H; Chayama K
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179077
[TBL] [Abstract][Full Text] [Related]
51. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
52. TM6SF2 rs58542926 is related to hepatic steatosis, fibrosis and serum lipids both in adults and children: A meta-analysis.
Li XY; Liu Z; Li L; Wang HJ; Wang H
Front Endocrinol (Lausanne); 2022; 13():1026901. PubMed ID: 36353245
[TBL] [Abstract][Full Text] [Related]
53. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.
Goffredo M; Caprio S; Feldstein AE; D'Adamo E; Shaw MM; Pierpont B; Savoye M; Zhao H; Bale AE; Santoro N
Hepatology; 2016 Jan; 63(1):117-25. PubMed ID: 26457389
[TBL] [Abstract][Full Text] [Related]
54. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
55. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
[TBL] [Abstract][Full Text] [Related]
56. Relationships among N,N-dimethylformamide exposure, CYP2E1 and TM6SF2 genes, and non-alcoholic fatty liver disease.
Zhou Z; Sang L; Wang J; Song L; Zhu L; Wang Y; Xiao J; Lian Y
Ecotoxicol Environ Saf; 2021 Nov; 228():112986. PubMed ID: 34794021
[TBL] [Abstract][Full Text] [Related]
57. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
[TBL] [Abstract][Full Text] [Related]
58. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.
Kozlitina J; Smagris E; Stender S; Nordestgaard BG; Zhou HH; Tybjærg-Hansen A; Vogt TF; Hobbs HH; Cohen JC
Nat Genet; 2014 Apr; 46(4):352-6. PubMed ID: 24531328
[TBL] [Abstract][Full Text] [Related]
59. Transmembrane 6 superfamily member 2 167K allele improves renal function in children with obesity.
Marzuillo P; Di Sessa A; Cirillo G; Umano GR; Pedullà M; La Manna A; Guarino S; Miraglia Del Giudice E
Pediatr Res; 2020 Aug; 88(2):300-304. PubMed ID: 31923913
[TBL] [Abstract][Full Text] [Related]
60.
Lisboa QC; Nardelli MJ; Pereira PA; Miranda DM; Ribeiro SN; Costa RSN; Versiani CA; Vidigal PVT; Ferrari TCA; Couto CA
World J Hepatol; 2020 Oct; 12(10):792-806. PubMed ID: 33200017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
